BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26423799)

  • 1. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
    Watanabe M; Watanabe N; Maruyama S; Kawashiro T
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
    Kim J; Coss CC; Barrett CM; Mohler ML; Bohl CE; Li CM; He Y; Veverka KA; Dalton JT
    Int J Cancer; 2013 Mar; 132(6):1475-85. PubMed ID: 22915089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
    Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
    Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
    Desta Z; Ward BA; Soukhova NV; Flockhart DA
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes.
    Berthou F; Dreano Y; Belloc C; Kangas L; Gautier JC; Beaune P
    Biochem Pharmacol; 1994 May; 47(10):1883-95. PubMed ID: 8204106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
    Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
    Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
    Dehal SS; Kupfer D
    Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
    Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
    Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics.
    Edavana VK; Dhakal IB; Yu X; Williams S; Kadlubar S
    Drug Metab Dispos; 2012 Jun; 40(6):1210-5. PubMed ID: 22434874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver.
    Hashiba M; Kasahara T; Kim SY; Shibutani S; Degawa M
    Cancer Sci; 2006 Jun; 97(6):468-77. PubMed ID: 16734724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
    Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
    Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
    Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
    Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
    Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
    Dehal SS; Kupfer D
    Drug Metab Dispos; 1999 Jun; 27(6):681-8. PubMed ID: 10348797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.
    Sun D; Sharma AK; Dellinger RW; Blevins-Primeau AS; Balliet RM; Chen G; Boyiri T; Amin S; Lazarus P
    Drug Metab Dispos; 2007 Nov; 35(11):2006-14. PubMed ID: 17664247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in the research of pharmacogenomics of tamoxifen].
    Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
    Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.
    Greer AK; Dates CR; Starlard-Davenport A; Edavana VK; Bratton SM; Dhakal IB; Finel M; Kadlubar SA; Radominska-Pandya A
    Drug Metab Dispos; 2014 Sep; 42(9):1392-400. PubMed ID: 24917585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.